- Home
- GSIW vs GTBP Comparison
GSIW vs GTBP Comparison
Compare GSIW & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | GTBP |
|---|---|---|
| Founded | 2016 | 1965 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.9M | 2.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GSIW | GTBP |
|---|---|---|
| Price | $0.13 | $0.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 329.0K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,368,221.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 283.23 | N/A |
| 52 Week Low | $0.09 | $0.54 |
| 52 Week High | $1.79 | $4.10 |
Technical Indicators
Market Signals| Indicator | GSIW | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 56.99 |
| Support Level | $0.13 | $0.63 |
| Resistance Level | $0.14 | $0.75 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 11.46 | 77.87 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.